Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (181-190 of 257) with videos related to

Pageof 26
Sort By:
Blood|January 25, 2002
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trialPhilippe Moreau, Thierry Facon, Michel Attal, et al.
Haematologica|December 15, 2015
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myelomaMeletios A Dimopoulos, Matthew C Cheung, Murielle Roussel, et al.
Lancet (London, England)|October 9, 2007
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialThierry Facon, Jean Yves Mary, Cyrille Hulin, et al.
Blood|October 20, 2020
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myelomaJill Corre, Aurore Perrot, Denis Caillot, et al.
European Journal of Haematology|February 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported OutcomesAurore Perrot, Thierry Facon, Torben Plesner, et al.
Leukemia|January 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA studyPhilippe Moreau, Thierry Facon, Saad Z Usmani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialCyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
The translocation t(4;14) can be present only in minor subclones in multiple myelomaBenjamin Hébraud, Denis Caillot, Jill Corre, et al.
Hemasphere|November 15, 2019
Insights on Multiple Myeloma Treatment StrategiesMaría-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
Pageof 26

Showing results (181-190 of 257) with videos related to

Sort By:
Pageof 26
Blood|January 25, 2002
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trialPhilippe Moreau, Thierry Facon, Michel Attal, et al.
Haematologica|December 15, 2015
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myelomaMeletios A Dimopoulos, Matthew C Cheung, Murielle Roussel, et al.
Lancet (London, England)|October 9, 2007
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialThierry Facon, Jean Yves Mary, Cyrille Hulin, et al.
Blood|October 20, 2020
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myelomaJill Corre, Aurore Perrot, Denis Caillot, et al.
European Journal of Haematology|February 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported OutcomesAurore Perrot, Thierry Facon, Torben Plesner, et al.
Leukemia|January 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA studyPhilippe Moreau, Thierry Facon, Saad Z Usmani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialCyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
The translocation t(4;14) can be present only in minor subclones in multiple myelomaBenjamin Hébraud, Denis Caillot, Jill Corre, et al.
Hemasphere|November 15, 2019
Insights on Multiple Myeloma Treatment StrategiesMaría-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
Pageof 26